Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie

AstraZeneca lifts full-year outlook on upbeat demand for therapies By Reuters

AstraZeneca lifts full-year outlook on upbeat demand for therapies…

Half-year Report

AstraZeneca 25 July 2024 H1 and Q2 2024 results Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core…

Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Audi, Renault, Nissan Motor, AstraZeneca und Hermes

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups 24 View

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of…

Lloyds, AstraZeneca, British Gas owner and more: Day ahead on Thursday

Is AstraZeneca set for another upgrade: ... read preview BT has had a tough first half according to one leading City firm,…

Tagesvorschau: Marktgeschehen am 25. Juli

Eine wahren Datenflut erwartet uns am DonnerstagHeute stehen zahlreiche Unternehmensberichte an, darunter die Halbjahreszahlen von Audi, Hermes, Roche und AstraZeneca.…

Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?

Sales of AstraZenecas (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new…

AstraZeneca Stock: Upgrading From Hold To Buy Ahead Of Q2 2024 Earnings

…

AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?

AstraZenecas (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several…

Acquisition of Amolyt Pharma completed

15 July 2024 Acquisition of Amolyt Pharma completed AstraZeneca today announced the successful completion of theacquisition (https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-to-acquire-amolyt.html) of Amolyt Pharma, a clinical-stage biotechnology company focused…

dpa-AFX ProFeed